Participated · Series A · Mar 2026

Antiverse combines proprietary generative machine-learning models with programmable cell-line engineering to rapidly create epitope-specific, therapeutic-grade antibodies against difficult targets such as GPCRs and ion channels. Its lab-in-the-loop workflow reportedly reduces de novo antibody development timelines to under four months, integrating in-silico design with in-house build and validation. The company supports partnered discovery programs with several top-20 pharmaceutical firms and has just launched a research collaboration with the Cystic Fibrosis Foundation to generate antibodies targeting the extracellular region of CFTR. Backed by more than $20 million in total funding, Antiverse is expanding its platform, accelerating its internal pipeline, and intends to move its first wholly owned candidates into later-stage preclinical development by 2027. Headquartered in Cardiff, UK, with offices in Boston and Prague, the team has spent seven years training its models on challenging targets to optimize physicochemical properties and humanness of antibodies. Antiverse offers flexible collaboration structures to biotechnology, pharmaceutical, and foundation partners while simultaneously advancing its own therapeutics.